# Two Sigma Investments LP

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/two-sigma-investments-lp
Canonical HTML page: https://getyourbrief.com/entity/two-sigma-investments-lp

## Timeline

- **2026-08-14**: Quarterly earnings release — Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
- **2026-07-29**: Weiss Ratings upgrade — Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
- **2026-05-23**: Wall Street Zen rating action — Research note on LTRN reported with conflicting direction across sources (upgrade to hold vs downgrade to sell).

## Recent coverage (4 stories, network-wide)

### Lantern Pharma Misses EPS by $0.19; AI Oncology Stock Sits 44% Below High
2026-08-16 16:15:06 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
Full story: https://gethealthbrief.com/story/lantern-pharma-eps-miss-health-ai-oncology

### LTRN Misses EPS by $0.19 Yet Rises 0.8% to $2.65 on 2.3x Volume
2026-08-16 16:14:56 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Full story: https://getfinancebrief.com/story/ltrn-q2-earnings-miss-stock-reaction

### Lantern Pharma Posts $0.57 Loss, Misses Consensus by $0.19; Sell Rating Stands
2026-08-16 16:14:45 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Full story: https://getbiobrief.com/story/lantern-pharma-clinical-stage-eps-miss

### Retail Partner Cardlytics Sees CEO Sell $70K as Stock Tanks 87% to $4.37
2026-08-12 11:34:01 · Sector: retail · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Cardlytics, whose platform powers cashback offers inside banking apps for major retailers, is under financial strain—its stock has plummeted to $4.37 and the CEO has unloaded shares. The company’s tiny $25M market cap and negative earnings put its future in doubt, directly affecting retail brands that depend on it for consumer acquisition and loyalty campaigns.
Full story: https://getretailbrief.com/story/cardlytics-insider-selling-retail-partner-risk

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.